Novo Nordisk to Cut Semaglutide List Prices by 35‑50% – Wegovy, Ozempic, Rybelsus Standardized at $675/Month
CompanyDrug

Novo Nordisk to Cut Semaglutide List Prices by 35‑50% – Wegovy, Ozempic, Rybelsus Standardized at $675/Month

CompanyDeals

Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development

Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint
CompanyDeals

Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint

CompanyDrug

SinoMab’s First‑in‑Class IL‑25R Antibody SM17 Wins NMPA IND Approval – Novel IBD Therapy Enters Clinic

CompanyDrug

Hengrui’s ANGPTL3 Antibody SHR-1918 NDA Accepted by NMPA – Priority Review for Rare Disease HoFH

CompanyDrug

Pharscin Pharma’s PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval – First Class 1.1 Innovative Drug Enters Clinic

CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion – MCV4 Now Covers Children Up to 6 Years
CompanyDrug

CanSino Biologics Wins NMPA Approval for Menhycia Age Expansion – MCV4 Now Covers Children Up to 6 Years

Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets – AI‑Driven Multi‑Omics Analysis
CompanyDeals

Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets – AI‑Driven Multi‑Omics Analysis

CompanyDeals

YolTech Partners with XtalPi to Build AI‑Driven mRNA and CAR‑T Screening Platform – Closed‑Loop Dry‑Wet Lab Integration

J&J Invests $1B+ in Pennsylvania Cell Therapy Facility – Expands Manufacturing for Cancer and Neurology Pipeline
Company

J&J Invests $1B+ in Pennsylvania Cell Therapy Facility – Expands Manufacturing for Cancer and Neurology Pipeline

CompanyDeals

Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal – Expands Global RNAi Partnership

J&J's RYBREVANT SC Dosing Approved by EC – Expands Subcutaneous Options Across All NSCLC Indications
CompanyDrug

J&J’s RYBREVANT SC Dosing Approved by EC – Expands Subcutaneous Options Across All NSCLC Indications